Back Tuberculosis

ICAAC 2012: Experimental Nitroimidazole TBA-354 Shows Promise against Tuberculosis in Early Studies

The experimental nitroimidazole TBA-354, under investigation by the TB Alliance, showed potent activity against Mycobacterium tuberculosis in vitro and in animal studies, according to a presentation this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco. alt

Read more:

AIDS 2012: No Interactions Seen Between New TB Drug and Popular HIV Meds

The promising experimental tuberculosis (TB) drug delamanid does not interact with the widely used antiretrovirals tenofovir (Viread) and lopinavir/ritonavir (Kaletra) in ways likely to cause clinical problems, researchers reported at the XIX International AIDS Conference (AIDS 2012) last month in Washington, DC.

Read more:

AIDS 2012: Isoniazid Preventive Therapy Reduces Risk of TB for HIV+ People on ART

Twelve months of isoniazid (INH) preventive therapy (IPT) significantly reduced the incidence of all tuberculosis (TB) diagnoses among HIV positive people who were taking concurrent antiretroviral therapy (ART) according to results of a large randomized study presented as a late-breaker at the recent XIX International AIDS Conference (AIDS 2012) in Washington, DC.

alt

Read more:

Homeless People Have Higher Rates of HIV, Hepatitis C, and TB

Rates of HIV, hepatitis C, and tuberculosis (TB) vary considerably among homeless populations, but are significantly higher overall than those of people with stable housing, according to a study published in the August 20, 2012, advance online edition of Lancet Infectious Diseases.alt

Read more:

AIDS 2012: Novel PzMA Tuberculosis Combo Shows Potent Activity in Short-term Trial

A triple-combination regimen consisting of the experimental tuberculosis (TB) drug PA-824, the established TB drug pyrazinamide, and the widely used antibiotic moxifloxacin -- dubbed PaMZ -- showed potent bactericidal activity in a randomized 14-day study presented last week at the XIX International AIDS Conference (AIDS 2012) in Washington, DC, and published simultaneously in the July 23, 2012 issue of The Lancet.

Read more: